Pharmaids Pharmaceuticals Ltd
Pharmaids Pharmaceuticals Ltd (PHARMAID) last reported results for the quarter ended Jun 2026, with sales of ₹4.12 crore and net profit of ₹1.88 crore. The stock last traded at ₹30, a market capitalisation of ₹106 crore. Over the past 52 weeks the stock has ranged between ₹25.6 and ₹60. Figures are as of 6 Oct 2026 and are not real time.
Pharmaids Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹30
- Market cap
- ₹106 cr
- Book value
- ₹13.5
- ROE
- -26.5%
- ROCE
- -18.5%
- Dividend yield
- 0.00%
- 52w high / low
- 60.0/25.6
Metrics as of 6 Oct 2026. Not real time.
Track Pharmaids Pharmaceuticals Ltd
Cruxal reads every Pharmaids Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Pharmaids Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 19%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -50%
- TTM
- 17%
- 10 Years
- 23%
- 5 Years
- 15%
- 3 Years
- -11%
- 1 Year
- -46%
- 10 Years
- %
- 5 Years
- -21%
- 3 Years
- -19%
- Last Year
- -27%
Pharmaids Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹4.12 cr, down 38.1% from ₹6.66 cr a year earlier. Net profit turned positive at ₹1.88 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5.24 | 4.71 | 4.77 | 6.66 | 8.61 | 5.43 | 7.18 | 4.12 |
| Expenses | 7.65 | 7.6 | 8.67 | 12.03 | 13.93 | 7.94 | 7.52 | 4.87 |
| Operating profit | -2.41 | -2.89 | -3.9 | -5.37 | -5.32 | -2.51 | -0.34 | -0.75 |
| OPM % | -45.99% | -61.36% | -81.76% | -80.63% | -61.79% | -46.22% | -4.74% | -18.20% |
| Other income | 0.08 | 0 | 0.13 | 0.04 | 3.03 | -0.32 | 0.01 | 4.25 |
| Interest | 0.33 | 0.48 | 1.01 | 1.2 | 0.93 | 0.72 | 0.65 | 0.6 |
| Depreciation | 0.61 | 0.64 | 0.62 | 0.61 | 0.47 | 0.48 | 0.48 | 0.49 |
| Profit before tax | -3.27 | -4.01 | -5.4 | -7.14 | -3.69 | -4.03 | -1.46 | 2.41 |
| Tax % | -30.58% | -24.94% | -11.11% | -26.05% | -30.62% | -34.24% | -25.34% | 22.41% |
| Net profit | -2.27 | -3.01 | -4.8 | -5.27 | -2.57 | -2.65 | -1.09 | 1.88 |
| EPS (₹) | -0.55 | -0.55 | -1.12 | -1.39 | -0.71 | -0.70 | -0.51 | 0.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Pharmaids Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 3.94 | 0 | 15.11 | 19.45 | 27.88 | 25.34 |
| Operating profit | 0.13 | -9.89 | -12.35 | -12.75 | -13.51 | -8.92 |
| OPM % | 3.30% | — | -81.73% | -65.55% | -48.46% | -35.20% |
| Net profit | 0.15 | -7.56 | -11.85 | -13.51 | -11.57 | -4.43 |
| EPS (₹) | 0.15 | -3.52 | -2.26 | -3.06 | -3.32 | -1.29 |
TTM is the trailing twelve months to the most recent quarter.
Pharmaids Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 10.27 | 21.44 | 35.27 | 35.27 | 35.27 |
| Reserves | -1.60 | 1.02 | 36.78 | 24.05 | 12.39 |
| Borrowings | 0.00 | 0.00 | 8.53 | 38.98 | 23.39 |
| Other liabilities | 2.44 | 2.13 | 10.75 | 21.54 | 16.21 |
| Total liabilities | 11.11 | 24.59 | 91.33 | 119.84 | 87.26 |
| Fixed assets | 0.03 | 0.11 | 63.42 | 76.61 | 53.94 |
| CWIP | 0.45 | 2.00 | 7.00 | 4.53 | 6.10 |
| Investments | 0.00 | 3.31 | 0.00 | 0.00 | 0.00 |
| Other assets | 10.63 | 19.17 | 20.91 | 38.70 | 27.22 |
| Total assets | 11.11 | 24.59 | 91.33 | 119.84 | 87.26 |
As reported by the company. Total assets equal total liabilities by construction.
Pharmaids Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | -0.26 | -4.02 | -10.62 | -15.11 | -4.06 |
| Cash from investing | 0.47 | -4.94 | -74.99 | -12.22 | 23.34 |
| Cash from financing | 0.00 | 21.31 | 77.66 | 23.36 | -19.97 |
| Net cash flow | 0.21 | 12.35 | -7.95 | -3.98 | -0.69 |
| Free cash flow | -0.26 | -5.69 | -33.33 | -27.37 | 11.05 |
| CFO / operating profit | -200% | 41% | 86% | 118% | 30% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Pharmaids Pharmaceuticals Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | -63.67% | -25.99% | -17.43% | -18.48% |
| Debtor days | 124.14 | — | 64.74 | 58.74 | 44.90 |
| Inventory days | 90.99 | 0.00 | 111.61 | 346.51 | 8.73 |
| Days payable | 236.18 | — | 159.18 | 464.29 | 59.17 |
| Cash conversion cycle | -21.05 | — | 17.17 | -59.04 | -5.54 |
| Working capital days | -17.60 | — | -68.60 | -160.26 | -172.16 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Pharmaids Pharmaceuticals Ltd shareholding pattern
Promoters held 32.99% at Jun 2026, up from 5.14% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 5.19% | 5.22% | 5.22% | 5.14% | 32.99% | 32.99% | 32.99% | 32.99% |
| Public | 94.81% | 94.79% | 94.78% | 94.87% | 67.00% | 67.01% | 67.00% | 67.02% |
| No. of shareholders | 8,049 | 8,349 | 8,220 | 8,026 | 8,027 | 8,288 | 8,406 | 8,632 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Pharmaids Pharmaceuticals Ltd corporate filings
- Intimation w.r.t Closure of Trading WindowInsider Trading / SASTlow impact
- Pharmaids Pharmaceuticals files legal complaints against Anugraha Chemicals for cheque dishonourCompany Updatelow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Ltd has filed two legal complaints on September 15, 2026…
Read the full analysis - Pharmaids Pharmaceuticals Limited Announces Successful Conclusion of 37th Annual General Meeting and Approval of Related Party TransactionsAGM/EGMlow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Limited has successfully concluded its 37th Annual General…
Read the full analysis - Pharmaids Pharmaceuticals Limited concludes 37th Annual General Meeting; seeks approval for material related party transactionsAGM/EGMlow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Limited held its 37th Annual General Meeting on September 11…
Read the full analysis - Pharmaids Pharmaceuticals Ltd announces 37th Annual General Meeting scheduled for August 19, 2026Company Updatelow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Ltd has published a newspaper advertisement regarding the…
Read the full analysis - Pharmaids Pharmaceuticals Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Ltd has filed its Annual Report for the financial year 2025-26…
Read the full analysis - Pharmaids Pharmaceuticals Limited Announces 37th AGM and Releases Annual Report for FY 2025-26AGM/EGMlow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Limited has scheduled its 37th Annual General Meeting for…
Read the full analysis - Pharmaids Pharmaceuticals Limited Reports Q1 FY2027 Financial Results via Newspaper AdvertisementCompany Updatelow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Limited has published its unaudited financial results for the…
Read the full analysis - Pharmaids Pharmaceuticals Reports Q1 FY27 Results with Exceptional Items Driving Turnaround to ProfitabilityBoard Meetingmedium impact
Cruxal's analysis: Pharmaids Pharmaceuticals Limited reported a standalone net profit of 2.13 crore for the…
Read the full analysis - Pharmaids Pharmaceuticals Limited schedules Board Meeting for August 12, 2026, to approve Q1 FY2027 financial resultsBoard Meetinglow impact
Cruxal's analysis: Pharmaids Pharmaceuticals Limited has formally intimated the BSE regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.